Y-mAbs Therapeutics, Inc.
YMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $347,096 | $297,662 | $213,274 | $699,977 |
| - Cash | $67,234 | $78,637 | $105,762 | $181,564 |
| + Debt | $820 | $1,419 | $1,767 | $3,634 |
| Enterprise Value | $280,682 | $220,444 | $109,279 | $522,047 |
| Revenue | $87,685 | $84,819 | $65,267 | $34,897 |
| % Growth | 3.4% | 30% | 87% | – |
| Gross Profit | $72,434 | $73,403 | $57,700 | $32,383 |
| % Margin | 82.6% | 86.5% | 88.4% | 92.8% |
| EBITDA | -$30,666 | -$24,937 | -$94,729 | -$54,493 |
| % Margin | -35% | -29.4% | -145.1% | -156.2% |
| Net Income | -$29,666 | -$21,427 | -$95,568 | -$55,275 |
| % Margin | -33.8% | -25.3% | -146.4% | -158.4% |
| EPS Diluted | -0.67 | -0.49 | -2.2 | -1.28 |
| % Growth | -36.7% | 77.7% | -71.9% | – |
| Operating Cash Flow | -$15,714 | -$27,232 | -$75,921 | -$102,556 |
| Capital Expenditures | $0 | $0 | $0 | -$967 |
| Free Cash Flow | -$15,714 | -$27,232 | -$75,921 | -$103,523 |